AU2001296333A1 - Paad domain-containing polypeptides, encoding nucleic acids, and methods of use - Google Patents
Paad domain-containing polypeptides, encoding nucleic acids, and methods of useInfo
- Publication number
- AU2001296333A1 AU2001296333A1 AU2001296333A AU2001296333A AU2001296333A1 AU 2001296333 A1 AU2001296333 A1 AU 2001296333A1 AU 2001296333 A AU2001296333 A AU 2001296333A AU 2001296333 A AU2001296333 A AU 2001296333A AU 2001296333 A1 AU2001296333 A1 AU 2001296333A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- nucleic acids
- encoding nucleic
- containing polypeptides
- paad domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67176000A | 2000-09-26 | 2000-09-26 | |
US09/671,760 | 2000-09-26 | ||
PCT/US2001/030160 WO2002026780A2 (en) | 2000-09-26 | 2001-09-26 | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001296333A1 true AU2001296333A1 (en) | 2002-04-08 |
Family
ID=24695772
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001296333A Abandoned AU2001296333A1 (en) | 2000-09-26 | 2001-09-25 | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use |
AU9633301A Pending AU9633301A (en) | 2000-09-26 | 2001-09-26 | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU9633301A Pending AU9633301A (en) | 2000-09-26 | 2001-09-26 | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use |
Country Status (2)
Country | Link |
---|---|
AU (2) | AU2001296333A1 (en) |
WO (1) | WO2002026780A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
DE10100586C1 (en) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7041643B2 (en) | 2001-01-31 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Molecules of the PYRIN/NBS/LRR protein family and uses thereof |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
DE10163098B4 (en) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Method for inhibiting the replication of viruses |
DE10202419A1 (en) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Method of inhibiting expression of a target gene resulting from chromosome aberration |
WO2010138555A2 (en) | 2009-05-26 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Small peptide expression system in mammalian cells |
EP2968613B1 (en) | 2013-03-11 | 2019-09-11 | University of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
EP4050020A1 (en) * | 2014-03-11 | 2022-08-31 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
CN111690687B (en) * | 2020-07-28 | 2021-12-21 | 华南农业大学 | Method and application for promoting skeletal muscle development |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001251695A1 (en) * | 2000-02-17 | 2001-08-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
-
2001
- 2001-09-25 AU AU2001296333A patent/AU2001296333A1/en not_active Abandoned
- 2001-09-26 WO PCT/US2001/030160 patent/WO2002026780A2/en active Application Filing
- 2001-09-26 AU AU9633301A patent/AU9633301A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002026780A2 (en) | 2002-04-04 |
WO2002026780A3 (en) | 2003-05-22 |
AU9633301A (en) | 2002-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002214531A1 (en) | Proteins and nucleic acids encoding same | |
WO2003023008A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2001296333A1 (en) | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use | |
AU2002356534A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2001288390A1 (en) | Proteins and nucleic acids encoding same | |
AU2001239889A1 (en) | Polypeptides and nucleic acids encoding same | |
AU2003247537A1 (en) | Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof | |
AU2003217956A1 (en) | Therapeutic polypeptides, nucleic acids encoding same and methods of use | |
WO2002094870A8 (en) | Proteins and nucleic acids encoding same | |
AU2002365905A1 (en) | Transaminases, nucleic acids encoding them and methods of making and using them | |
WO2003040330A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2003083039A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
EP1532238A4 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2002333654A1 (en) | Mcfp encoding nucleic acids, polypeptides, antibodies and methods of use thereof | |
EP1399537A4 (en) | Therapeutic polypeptides, nucleic acids encoding same and methods of use | |
AU2001264934A1 (en) | Dna repair polypeptides and methods of use | |
AU2002211681A1 (en) | Proteins and nucleic acids encoding same | |
AU2002365216A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2002365189A1 (en) | P85-alpha nucleic acids, polypeptides and related methods | |
AU2002230994A1 (en) | Proteins and nucleic acids encoding same | |
AU2001232804A1 (en) | Nucleic acids encoding human semaphorin proteins and use thereof | |
AU2001234896A1 (en) | Novel polypeptides and nucleic acids encoding same | |
AU2003304034A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2003060149A9 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU3045301A (en) | Novel glutathione-s-transferase nucleic acids and polypeptides and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |